Editorial: Applications of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): State of the Art

Silva, Ana Catarina; Amaral, Maria Helena; Lobo, José Manuel Sousa; Almeida, Hugo

doi:10.2174/1381612824666171214102607

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLNs are colloidal carrier systems composed of one or more lipids, solid at room conditions, coated by hydrophilic surfactant(s) [ 16 , 17 ]. The term ‘lipid’ is used in a broader sense and includes triglycerides, cetyl palmitate, alkanoic acids, and various synthetic or naturally occurring lipophilic materials, all however characterized by a high level of biocompatibility [ 18 , 19 ]. The main advantages of SLN versus other colloidal drug carriers include the possibility of achieving a controlled drug release, while increasing the physicochemical stability of loaded drugs, both lipophilic and hydrophilic compounds [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

A Method for Efficient Loading of Ciprofloxacin Hydrochloride in Cationic Solid Lipid Nanoparticles: Formulation and Microbiological Evaluation

et al. 2018

View full text Add to dashboard Cite

The aim of the study was the production of solid lipid nanoparticles (SLN) loaded with ciprofloxacin (CIP) through two different production techniques, quasi-emulsion solvent diffusion (QESD) and solvent injection (SI). In order to efficaciously entrap the commercial salt form (hydrochloride) of the antibiotic in these lipid systems, a conversion of CIP hydrochloride to the free base was realized in situ, through the addition of triethylamine. To ensure physical stability to the carriers over time and ameliorate the interaction with bacterial cell membranes, positively charged SLN were produced by addition of the cationic lipid didecyldimethylammonium bromide (DDAB). Homogeneous SLN populations with a mean particle sizes of 250–350 nm were produced by both methods; drug encapsulation was over 85% for most samples. The SLN were physically stable for up to nine months both at 4 °C and 25 °C, although the former condition appears more suitable to guarantee the maintenance of the initial particle size distribution. As expected, CIP encapsulation efficiency underwent a slight reduction after nine months of storage, although the initial high drug content values would ensure a residual concentration of the antibiotic in the SLN still appropriate to exert an acceptable antibacterial activity. Selected SLN formulations were subjected to an in vitro microbiological assay against different bacterial strains, to verify the effect of nanoencapsulation on the cell growth inhibitory activity of CIP. In general, CIP-SLN produced without DDAB showed MIC values for CIP comparable to those of the free drug. Conversely, addition of increasing percentages of the cationic lipid, reflected by a progressive increase of the positive value of the Zeta potential, showed a variety of MIC values against the various bacterial strains, but with values 2–4 order of dilution lower than free CIP. An hypothesis of the effect of the cationic lipid upon the increased antibacterial activity of CIP in the nanocarriers is also formulated.

show abstract